The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Riociguat for the Treatment of Pulmonary Arterial Hypertension
Open accessAbstract
Background Riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase 2 trial to be beneficial in the treatment of pulmonary arterial hypertension. Methods In this phase 3, double-blind study, we randomly assigned 443 patients with symptomatic pulmonary arterial hypertension to receive placebo, riociguat in individually adjusted doses of up to 2.5 mg three times daily (2.5 mg-maximum group), or riociguat in individually adjusted doses that were capped at 1.5 mg three times daily (1.5 mg-maximum group). The 1.5 mg-maximum group was included for exploratory purposes, and the data from that group were analyzed descriptively. Patients who were receiving no other treatment for pulmonary arterial hypertension and patients who were receiving endothelin-receptor antagonists or (nonintravenous) prostanoids were eligible. The primary end point was the change from baseline to the end of week 12 in the distance walked in 6 minutes. Secondary end points included the change in pulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, World Health Organization (WHO) functional class, time to clinical worsening, score on the Borg dyspnea scale, quality-of-life variables, and safety. Results By week 12, the 6-minute walk distance had increased by a mean of 30 m in the 2.5 mg-maximum group and had decreased by a mean of 6 m in the placebo group (least-squares mean difference, 36 m; 95% confidence interval, 20 to 52; P Conclusions Riociguat si…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given that most efficacious therapies for the treatment of PH involve targeting of NO signaling[48,49], it is clear that pulmonary vascular health is intimately tied to effective NO bioactivity.”
From Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health (2017) · cites this paper as [49]
Citations
Cites
Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Hoeper, M. M., Humbert, M. J. C., Torbicki, A., Vachiéry, J., Barberà, J. A., Beghetti, M., Corris, P. A., Gaine, S., Gibbs, J. S. R., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,853
Self-citationBosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., KEOGH, A. M., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,718
Self-citationBarst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. Μ., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,688
Self-citationSildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D. B., Fleming, T. R., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,466
Self-citationACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,359
Self-citationInhaled Iloprost for Severe Pulmonary Hypertension
Olschewski, H., Simonneau, G., Galiè, N., HIGENBOTTAM, T. W., Naeije, R., Rubin, L. J., Nikkho, S. M., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783
Self-citationRiociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Ghofrani, H. A., D’Armini, A. M., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Mayer, E., Simonneau, G., Wilkins, M. R., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209657 · Cited by 1,393
Self-citationMiyamoto, S., Nagaya, N., Satoh, T., Kyotani, S., Sakamaki, F., Fujita, M., Nakanishi, N., & Miyatake, K. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.9906015 · Cited by 1,147
Benza, R. L., Miller, D. P., Barst, R. J., Badesch, D. B., Frost, A., & McGoon, M. D. (2012) · CHEST Journal · doi:10.1378/chest.11-1460 · Cited by 1,107
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192230 · Cited by 1,096
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,000
Khanna, D., Allanore, Y., Denton, C. P., Kuwana, M., Matucci‐Cerinic, M., Pope, J. E., Atsumi, T., Bečvář, R., Czirják, L., HACHULLA, E., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216823 · Cited by 111
The Endothelium-Dependent Nitric Oxide–cGMP Pathway
Mónica, F. Z., Bian, K., & Murad, F. (2016) · Advances in pharmacology · doi:10.1016/bs.apha.2016.05.001 · Cited by 114
Riociguat for pulmonary arterial hypertension associated with congenital heart disease
Rosenkranz, S., Ghofrani, H. A., Beghetti, M., Ivy, D. D., Frey, R., Fritsch, A., Weimann, G., Saleh, S., & Apitz, C. (2015) · Heart · doi:10.1136/heartjnl-2015-307832 · Cited by 109
Self-citationRisk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Humbert, M. J. C., Farber, H. W., Ghofrani, H. A., Benza, R. L., Busse, D., Meier, C., & Hoeper, M. M. (2019) · European Respiratory Journal · doi:10.1183/13993003.02004-2018 · Cited by 108
Self-citationSoluble GC stimulators and activators: Past, present and future
Sandner, P., Follmann, M., Becker‐Pelster, E., Hahn, M. G., Meier, C., Freitas, C., Roessig, L., & Stasch, J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15698 · Cited by 107
Pulmonary Hypertension and Right Heart Dysfunction in Chronic Lung Disease
Zangiabadi, A., Pasquale, C. G. D., & Sajkov, D. (2014) · BioMed Research International · doi:10.1155/2014/739674 · Cited by 105
Viethen, T., Gerhardt, F., Dumitrescu, D., Knoop-Busch, S., ten Freyhaus, H., Rudolph, T. K., Baldus, S. E., & Rosenkranz, S. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.04.233 · Cited by 105
Raevens, S., Geerts, A. M., Steenkiste, C. V., Verhelst, X., Vlierberghe, H. V., & Colle, I. O. (2015) · Liver International · doi:10.1111/liv.12791 · Cited by 104
Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue
Hoffmann, L. S., Etzrodt, J., Willkomm, L., Sanyal, A., Scheja, L., Fischer, A. W., Stasch, J., Bloch, W., Friebe, A., Heeren, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms8235 · Cited by 103
Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension
Ghofrani, H. A., Humbert, M. J. C., Langleben, D., SCHERMULY, R. T., Stasch, J., Wilkins, M. R., & Klinger, J. R. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.05.024 · Cited by 103
Self-citationPulmonary arterial hypertension: updates in epidemiology and evaluation of patients
Levine, D. J. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88609 · Cited by 101
Mitochondrial dysfunction and pulmonary hypertension: cause, effect, or both
Marshall, J. D., Bazan, I. S., Zhang, Y., Fares, W. H., & Lee, P. J. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00331.2017 · Cited by 102
Six-minute walk test in pulmonary arterial hypertension
Demi̇r, R., & Küçükoğlu, M. S. (2015) · The Anatolian Journal of Cardiology · doi:10.5152/akd.2015.5834 · Cited by 99
Functional Characterization of the GUCY1A3 Coronary Artery Disease Risk Locus
Kessler, T., Wobst, J., Wolf, B. A., Eckhold, J., Vilne, B., Hollstein, R., von Ameln, S., Dang, T. A., Sager, H. B., Rumpf, P. M., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024152 · Cited by 100
5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure
Janssen, W., Schymura, Y., Novoyatleva, T., Kojonazarov, B. K., Boehm, M., Wietelmann, A., Luitel, H., Murmann, K., Krompiec, D., Tretyn, A., et al. (2015) · BioMed Research International · doi:10.1155/2015/438403 · Cited by 94
Self-citationSystemic sclerosis and localized scleroderma—current concepts and novel targets for therapy
Distler, O., & Cozzio, A. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0551-z · Cited by 92
Nitric Oxide-cGMP Signaling in Hypertension
Ataabadi, E. A., Golshiri, K., Jüttner, A. A., Krenning, G., Danser, A. H. J., & Roks, A. J. M. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15856 · Cited by 94
Weißmann, N., Lobo, B., Pichl, A., Parajuli, N., Seimetz, M., Puig-Pey, R., Ferrer, E., Peinado, V. I., Domínguez‐Fandos, D., Fysikopoulos, A., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201311-2037oc · Cited by 92
Self-citationFrom molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
Sandner, P. (2018) · Biological Chemistry · doi:10.1515/hsz-2018-0155 · Cited by 91
Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update
Coons, J. C., Pogue, K. T., Kolodziej, A., Hirsch, G. A., & George, M. P. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1235-4 · Cited by 89
Pharmacology and Clinical Drug Candidates in Redox Medicine
Dao, V. T.-V., Casas, A. I., Maghzal, G. J., Seredenina, T., Kaludercic, N., Robledinos-Anton, N., Di Lisa, F., Stocker, R., Ghezzi, P., Jaquet, V., et al. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6430 · Cited by 88
Regulation of soluble guanylyl cyclase redox state by hydrogen sulfide
Zhou, Z., Martin, E., Sharina, I. G., Esposito, I., Szabó, C., Bucci, M., Cirino, G., & Papapetropoulos, A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.029 · Cited by 88
Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension
the Australian Scleroderma Interest Group (ASIG), Morrisroe, K., Stevens, W., Huq, M. M., Prior, D., Sahhar, J., Ngian, G., Celermajer, D. S., Zochling, J., Proudman, S., et al. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1341-x · Cited by 87
Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment
Zanatta, E., Polito, P., Famoso, G., Larosa, M., Zorzi, E. D., Scarpieri, E., Cozzi, F., & Doria, A. (2019) · Experimental Biology and Medicine · doi:10.1177/1535370218824101 · Cited by 86
The cGMP system: components and function
Hofmann, F. B. (2019) · Biological Chemistry · doi:10.1515/hsz-2019-0386 · Cited by 88
Pulmonary hypertension phenotypes in patients with systemic sclerosis
Haque, A., Kiely, D. G., Kovács, G., Thompson, A. A. R., & Condliffe, R. A. (2021) · European Respiratory Review · doi:10.1183/16000617.0053-2021 · Cited by 85
Dachs, T.-M., Duca, F., Rettl, R., Binder, C., Dalos, D., Ligios, L. C., Kammerlander, A. A., Grünig, E., Pretsch, I., Steringer‐Mascherbauer, R., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac389 · Cited by 84
Self-citationBubb, K. J., Trinder, S. L., Baliga, R. S., Patel, J. A., Clapp, L. H., MacAllister, R. J., & Hobbs, A. J. (2014) · Circulation · doi:10.1161/circulationaha.114.009751 · Cited by 90
Mongirdienė, A., Skrodenis, L., Varoneckaitė, L., Mierkytė, G., & Gerulis, J. (2022) · Biomedicines · doi:10.3390/biomedicines10030602 · Cited by 86
Novel and Emerging Therapies for Pulmonary Hypertension
Pullamsetti, S. S., SCHERMULY, R. T., Ghofrani, H. A., Weißmann, N., Grimminger, F., & Seeger, W. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1543pp · Cited by 82
Self-citationCurrent and emerging therapeutic approaches to pulmonary hypertension
Bisserier, M., Pradhan, N. M., & Hadri, L. (2020) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2020.02.597 · Cited by 86
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis
McLaughlin, V. V., Hoeper, M. M., Badesch, D. B., Ghofrani, H. A., Gibbs, J. S. R., Gomberg‐Maitland, M., Preston, I. R., Souza, R., Waxman, A. B., Kopeć, G., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2508170 · Cited by 82
Self-citationDasgupta, A., Bowman, L., D’Arsigny, C. L., & Archer, S. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.10 · Cited by 84
Sex Differences in Response to Tadalafil in Pulmonary Arterial Hypertension
Mathai, S. C., Hassoun, P. M., Puhan, M. A., Zhou, Y., & Wise, R. A. (2014) · CHEST Journal · doi:10.1378/chest.14-0263 · Cited by 84
Lau, E., Tamura, Y., McGoon, M. D., & Sitbon, O. (2015) · European Respiratory Journal · doi:10.1183/13993003.01177-2015 · Cited by 82
Pulmonary Arterial Hypertension: Combination Therapy in Practice
Burks, M., Stickel, S., & Galiè, N. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0272-5 · Cited by 79
Self-citationRepurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again
Prins, K. W., Thenappan, T., Weir, Ε. K., Kalra, R., PRITZKER, M. R., & Archer, S. L. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.011343 · Cited by 80
Guidelines for the Treatment of Pulmonary Arterial Hypertension
Vazquez, Z. G. S., & Klinger, J. R. (2020) · Lung · doi:10.1007/s00408-020-00375-w · Cited by 78
Thoonen, R., Cauwels, A., Decaluwe, K., Geschka, S., Tainsh, R. E., Delanghe, J., Hochepied, T., De Cauwer, L., Rogge, E., Voet, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9482 · Cited by 77
EURASIAN CLINICAL GUIDELINES ON DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION
Chazova, I. E., Martynyuk, T. V., Солтановна, В. З., Азизов, В. А., Барбараш, О. Л., Veselova, T. N., Galyavich, A. S., Gorbachevsky, S. V., Zelveian, P., Лазарева, И. В., et al. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-1-78-122 · Cited by 76
Balistrieri, A., Makino, A., & Yuan, J. X. ‐. (2022) · Physiological Reviews · doi:10.1152/physrev.00030.2021 · Cited by 77
Hansmann, G., & Apitz, C. (2016) · Heart · doi:10.1136/heartjnl-2015-309103 · Cited by 76
Collum, S. D., Amione‐Guerra, J., Cruz-Solbes, A. S., DiFrancesco, A., Hernandez, A. M., Hanmandlu, A., Youker, K. A., Guha, A., & Karmouty‐Quintana, H. (2017) · Canadian Respiratory Journal · doi:10.1155/2017/1430350 · Cited by 76
Choosing sensitivity analyses for randomised trials: principles
Morris, T. P., Kahan, B. C., & White, I. R. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-11 · Cited by 75
“It is common for authors to compare the results of intention-to-treat with per-protocol analysis; see for example [8,9].”
BackgroundPulmonary arterial hypertension specific therapy: The old and the new
Zolty, R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107576 · Cited by 75
Hoeper, M. M., Apitz, C., Grünig, E., Halank, M., Ewert, R., Kaemmerer, H. M., Kabitz, H., Kähler, C. M., Klose, H. F. E., Leuchte, H. H., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.08.082 · Cited by 74
Self-citationTello, K., Seeger, W., Naeije, R., Vanderpool, R. R., Ghofrani, H. A., Richter, M. J., Tedford, R. J., & Bogaard, H. J. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14866 · Cited by 78
Self-citationFrantz, R. P., McLaughlin, V. V., Sahay, S., Subías, P. E., Zolty, R. L., Benza, R. L., Channick, R. N., Chin, K., Hemnes, A. R., Howard, L., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00072-9 · Cited by 79
Self-citationAvdeev, S. N., Барбараш, О. Л., Солтановна, В. З., Volkov, A. V., Veselova, T. N., Galyavich, A. S., Goncharova, N. S., Gorbachevsky, S. V., Владимирович, Г. В., Danilov, N. M., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6161 · Cited by 74
Buys, E. S., Zimmer, D. P., Chickering, J. G., Graul, R. M., Chien, Y., Profy, A. T., Hadcock, J. R., Masferrer, J. L., & Milne, G. T. (2018) · Nitric Oxide · doi:10.1016/j.niox.2018.05.009 · Cited by 75
Kuwana, M., Blair, C. J., Takahashi, T., Langley, J., & Coghlan, G. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216274 · Cited by 73
Benza, R. L., Grünig, E., Sandner, P., Stasch, J., & Simonneau, G. (2024) · European Respiratory Review · doi:10.1183/16000617.0183-2023 · Cited by 73
Self-citationBisping, E. H., Wakula, P., Poteser, M., & Heinzel, F. R. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000126 · Cited by 73
Pulmonary Arterial Hypertension
Dodson, M. W., Brown, L. M., & Elliott, C. G. (2018) · Heart Failure Clinics · doi:10.1016/j.hfc.2018.02.003 · Cited by 72
Pulmonary sarcoidosis: A comprehensive review: Past to present
Belperio, J. A., Fishbein, M. C., Abtin, F. G., Channick, J. E., Balasubramanian, S. A., & Lynch, J. P. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103107 · Cited by 75
The pathophysiology of pulmonary hypertension in left heart disease
Breitling, S., Ravindran, K., Goldenberg, N. M., & Kuebler, W. M. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00146.2015 · Cited by 72
Systemic sclerosis: Recent insights
Elhaï, M., Avouac, J., Kahan, A., & Allanore, Y. (2014) · Joint Bone Spine · doi:10.1016/j.jbspin.2014.10.010 · Cited by 71
Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
Frey, R., Becker, C., Saleh, S., Unger, S., van der Mey, D., & Mück, W. M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0604-7 · Cited by 71
Dees, C., Beyer, C., Distler, A., Soare, A., Zhang, Y., Palumbo‐Zerr, K., Distler, O., Schett, G. A., Sandner, P., & Distler, J. H. W. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206809 · Cited by 70
The evolving landscape of pulmonary arterial hypertension clinical trials
Weatherald, J. C., Boucly, A., Peters, A. E., Montani, D., Prasad, K., Psotka, M. A., Zannad, F. M., Gomberg‐Maitland, M., McLaughlin, V. V., Simonneau, G., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01601-4 · Cited by 71
Self-citationPulmonary hypertension associated with thalassemia syndromes
Fraidenburg, D. R., & Machado, R. F. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13037 · Cited by 72
Flores‐Costa, R., Alcaraz‐Quiles, J., Titos, E., López‐Vicario, C., Casulleras, M., Duran‐Güell, M., Rius, B., Díaz, A., Hall, K. M., Shea, C. M., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14137 · Cited by 69
Langhauser, F., Casas, A. I., Dao, V.-T.-V., Güney, E., Menche, J., Geuß, E., Kleikers, P. W. M., López, M. G., Barabási, A.-Ĺ., Kleinschnitz, C., et al. (2018) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0039-7 · Cited by 69
Gatzoulis, M. Α., Beghetti, M., Landzberg, M. J., & Galiè, N. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.09.024 · Cited by 68
Self-citationManagement of Pulmonary Arterial Hypertension
Mayeux, J. D., Pan, I. Z., Dechand, J., Jacobs, J. A., Jones, T. L., McKellar, S. H., Beck, E. M., Hatton, N. D., & Ryan, J. J. (2020) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-020-00663-3 · Cited by 68
Effect of Macitentan on Hospitalizations
Channick, R. N., Delcroix, M., Ghofrani, H. A., Hunsche, E., Jansa, P., Brun, F. L., Mehta, S., Pulido, T., Rubin, L. J., Sastry, B. K. S., et al. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2014.07.013 · Cited by 68
Self-citationPortopulmonary Hypertension: From Bench to Bedside
Thomas, C., Glinskii, V. V., Pérez, V. D. J., & Sahay, S. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.569413 · Cited by 67
Novel Insights Regarding Nitric Oxide and Cardiovascular Diseases
Infante, T., Costa, D., & Claudio Napoli, A. (2021) · Angiology · doi:10.1177/0003319720979243 · Cited by 72
Drug Treatment of Pulmonary Hypertension in Children
Vorhies, E. E., & Ivy, D. D. (2013) · Pediatric Drugs · doi:10.1007/s40272-013-0052-2 · Cited by 67
Myers, P. O., Tissot, C., & Beghetti, M. (2013) · Circulation Journal · doi:10.1253/circj.cj-13-1263 · Cited by 67
Treatment of pulmonary arterial hypertension in children
Gorenflo, M., & Ziesenitz, V. C. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-912 · Cited by 67
Khanna, D., Zhao, C., Saggar, R., Mathai, S. C., Chung, L. S., Coghlan, G., Shah, M., Hartney, J. M., & McLaughlin, V. V. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41669 · Cited by 66
Campochiaro, C., & Allanore, Y. (2021) · Arthritis Research & Therapy · doi:10.1186/s13075-021-02536-5 · Cited by 66
Beyond a single pathway: combination therapy in pulmonary arterial hypertension
Sitbon, O., & Gaine, S. (2016) · European Respiratory Review · doi:10.1183/16000617.0085-2016 · Cited by 66
Zheng, L., Li, S., Zhao, S., & Fa, X. (2016) · Medical Science Monitor · doi:10.12659/msm.900487 · Cited by 65
Riociguat: First Global Approval
Conole, D., & Scott, L. J. (2013) · Drugs · doi:10.1007/s40265-013-0149-5 · Cited by 65
Cartin‐Ceba, R., & Krowka, M. J. (2014) · Clinics in Liver Disease · doi:10.1016/j.cld.2014.01.004 · Cited by 64
Dasatinib‐induced pulmonary arterial hypertension
Yurttaş, N. Ö., & Eşkazan, A. E. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13508 · Cited by 63
Cardiac NO signalling in the metabolic syndrome
Pecháňová, O., Varga, Z. V., Cebová, M., Giricz, Z., Pacher, P., & Ferdinándy, P. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12960 · Cited by 63
Endothelial Cell Regulation of Pulmonary Vascular Tone, Inflammation, and Coagulation
Goldenberg, N. M., & Kuebler, W. M. (2015) · Comprehensive physiology · doi:10.1002/cphy.c140024 · Cited by 63
Pulmonary arterial hypertension
Boucly, A., Gerges, C., Savale, L., Jaïs, X., Jevnikar, M., Montani, D., Sitbon, O., & Humbert, M. J. C. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104168 · Cited by 61
Self-citationFraccarollo, D., Galuppo, P., Motschenbacher, S., Ruetten, H., Schäfer, A., & Bauersachs, J. K. (2014) · Basic Research in Cardiology · doi:10.1007/s00395-014-0421-1 · Cited by 61
Dardi, F., Manes, A., Palazzini, M., Bachetti, C., Mazzanti, G., Rinaldi, A., Albini, A., Gotti, E., Monti, E., Reggiani, M. L. B., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00209914 · Cited by 60
Self-citationPulmonary hypertension 2015: current definitions, terminology, and novel treatment options
Rosenkranz, S. (2014) · Clinical Research in Cardiology · doi:10.1007/s00392-014-0765-4 · Cited by 60
United States Pulmonary Hypertension Scientific Registry
Badlam, J. B., Badesch, D. B., Austin, E. D., Benza, R. L., Chung, W. K., Farber, H. W., Feldkircher, K., Frost, A., Poms, A. D., Lutz, K. A., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.07.088 · Cited by 60
Unni, S., Aouti, S., Thiyagarajan, S., & Padmanabhan, B. (2020) · Journal of Biosciences · doi:10.1007/s12038-020-00102-w · Cited by 63
Pulmonary hypertension in connective tissue diseases, new evidence and challenges
Vonk, M. C., Vandecasteele, E. H., & van Dijk, A. P. J. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13453 · Cited by 60
Hipertensión arterial pulmonar
Luna‐López, R., Martín, A. R., & Subías, P. E. (2022) · Medicina Clínica · doi:10.1016/j.medcli.2022.01.003 · Cited by 60
Li, F., Zhao, Y., Cheng, Z., Wang, Y., Yue, Y., Cheng, X., Sun, J., Atabakhshi‐Kashi, M., Yao, J., Dou, J., et al. (2023) · Advanced Materials · doi:10.1002/adma.202212206 · Cited by 61
Contemporary Treatment of Pulmonary Arterial Hypertension: A U.S. Perspective
Sahay, S., Chakinala, M. M., Kim, N. H., Preston, I. R., Thenappan, T., & McLaughlin, V. V. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202405-0914so · Cited by 60
Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension
Hoeper, M. M. (2015) · European Respiratory Review · doi:10.1183/16000617.00001015 · Cited by 60
Noël, S., Schmidt, B. Z., Haaf, J. B., & Leal, T. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s100759 · Cited by 64
Böettcher, M., Gerisch, M., Lobmeyer, M. T., Besche, N., Thomas, D., Gerrits, M., Lemmen, J., Mueck, W., Radtke, M., & Becker, C. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00895-x · Cited by 59
Pulmonary Hypertension in Children
Ivy, D. D. (2016) · Cardiology Clinics · doi:10.1016/j.ccl.2016.04.005 · Cited by 59
Cartin‐Ceba, R., Halank, M., Ghofrani, H. A., Humbert, M. J. C., Mattson, J., Fritsch, A., & Krowka, M. J. (2018) · Pulmonary Circulation · doi:10.1177/2045894018769305 · Cited by 58
Self-citationBuys, E. S., Potter, L. R., Pasquale, L. R., & Ksander, B. R. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00038 · Cited by 58
Diagnostic criteria, severity classification and guidelines of systemic sclerosis
Asano, Y., Jinnin, M., Kawaguchi, Y., Kuwana, M., Goto, D., Sato, S., Takehara, K., Hatano, M., Fujimoto, M., Mugii, N., et al. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14162 · Cited by 58
Marra, A. M., Halank, M., Benjamin, N., Bossone, E., Cittadini, A., Eichstaedt, C. A., Egenlauf, B., Harutyunova, S., Fischer, C., Gall, H. J., et al. (2018) · Respiratory Research · doi:10.1186/s12931-018-0957-y · Cited by 58
Self-citationAvdeev, S. N., Барбараш, О. Л., Баутин, А. Е., Volkov, A. V., Veselova, T. N., Galyavich, A. S., Goncharova, N. S., Gorbachevsky, S. V., Danilov, N. M., Еременко, А. А., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4683 · Cited by 57
The 6-min walk test as a primary end-point in interstitial lung disease
Harari, S. A., Wells, A. U., Wuyts, W. A., Nathan, S. D., Kirchgaessler, K.-U., Bengus, M., & Behr, J. (2022) · European Respiratory Review · doi:10.1183/16000617.0087-2022 · Cited by 57
Metadata
- Authors
- Ghofrani, H.-A., Galiè, N., Grimminger, F., Grünig, E., Humbert, M., Jing, Z.-C., Keogh, A. M., Langleben, D., Kilama, M. O., Fritsch, A., Neuser, D., & Rubin, L. J.
- Affiliations
- Justus-Liebig-Universität Gießen (DE)
- University of Bologna (IT)
- University Hospital Heidelberg (DE)
- Université Paris-Sud (FR)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- St Vincent's Hospital Sydney (AU)
- Jewish General Hospital (CA)
- Bayer (Italy) (IT)
- Bayer (Germany) (DE)
- University of California San Diego (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-25
- Volume
- 369
- Issue
- 4
- Pages
- 330-340
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2107011819
- Cited by
- 1,346
- References
- 26
- Citations by year
- 2026: 52 · 2025: 70 · 2024: 75 · 2023: 90 · 2022: 98 · 2021: 112 · 2020: 93 · 2019: 85 · 2018: 92 · 2017: 115 · 2016: 145 · 2015: 152 · 2014: 128 · 2013: 32
- FWCI
- 124.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- riociguat, pulmonary arterial hypertension, soluble guanylate cyclase stimulator, 6-minute walk distance, pulmonary vascular resistance, NT-proBNP, WHO functional class, dyspnea, endothelin receptor antagonists, prostanoids, dose adjustment, syncope, exercise capacity, quality of life, drug safety, drug efficacy
- MeSH terms
- Adult, Aged, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Hypertension, Pulmonary, Male, Middle Aged, Peptide Fragments, Prostaglandins, Pyrazoles, Pyrimidines, Quality of Life, Vascular Resistance, Walking, Exercise Tolerance, Natriuretic Peptide, Brain, Endothelin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
